David H. Johnson, MD
Deputy Director, Cornelius Abernathy Craig
Professor of Medical and Surgical Oncology,
Director, Division of Hematology/Oncology
Dr. Johnson is a medical oncologist who specializes in lung cancer, breast cancer, and experimental therapeutics, (developing and testing new anti-cancer treatment therapies). His clinical research efforts focus on the management of thoracic malignancies and the biology and treatment of breast cancers.
Dr. Johnson is a widely recognized investigator, the author of over 250 publications, editor or co-editor of numerous oncology textbooks and is actively involved in numerous professional associations including the American Society of Clinical Oncology (ASCO). Dr. Johnson is the Immediate Past President of ASCO which is the world's largest professional organization representing physicians who treat people with cancer. In 2004, Dr. Johnson was once again listed as one of the "top doctors" in the nation in America's Top Doctors rankings.
Marc E. Lippman, MD
Kathleen & Stanley Glaser Professor,
Chairman, Department of Medicine,
Leonard M. Miller School of Medicine
University of Florida, Miami
The work of Dr. Lippman, a renowned expert in breast cancer research, is noted for its focus on bridging the gap between basic tumor biology and clinical application. Prior to his appointments at the University of Floridan and the University of Michigan, he held a number of positions at Georgetown University Medical School, including Director of the Lombardi Cancer Research Center, Professor and Chairman of the Department of Oncology, Professor of Medicine, and Chief of the Division of Hematology-Oncology. He also served as Head of the Medical Breast Cancer Section of the Medicine Branch of the National Cancer Institute. Dr. Lippman is the recipient of the Clinical Investigator Prize of the American Federation for Clinical Research, the Rosenthal Award of the American Association for Cancer Research, the American Cancer Society Lectureship award given by the American Society for Clinical Oncology, the Astwood Prize of the Endocrine Society, and the Brinker International Prize for Basic Research in Breast Cancer. He is the author of more than 500 publications and one of the standard texts on breast cancer. With sponsorship from Health Care Ventures, he was a cofounder of Oncologix, a diagnostics company that was eventually sold to Aronex; and a cofounder of Peregrine Biotechnology, which was sold to Techniclone. He serves as chair of the Scientific Advisory Board for the Perseus-Soros Fund. In addition to his board position with Raven, Dr. Lippman is a Director of Seattle Genetics. He received a BA from Cornell University and his board position with an MD from Yale University.
Margaret Tempero, MD
Deputy Director, Comprehensive Cancer; Chief of Medical Oncology, Department of Medicine; and
Doris & Donald Fisher Distinguished Professor in Clinical Cancer Research;
University of California, San Francisco
Dr. Tempero's research interests include the development of the pancreas and diagnosis and treatment of pancreatic cancer. She has published more than 100 articles, books, and book chapters and serves on the editorial boards of the Journal of Clinical Oncology and Cancer Research. In addition, she serves on several review committees for the National Cancer Institute (NCI) and is a former Director for the American Society of Clinical Oncologists. Dr. Tempero is a member of the NCI pancreatic cancer SPORE grant facility.